How is Amycretin administered?
This describes how Amycretin is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous (sub-q form) or oral (oral form), on a once weekly (sub-q) or once daily (oral) schedule, generally over trial protocols. Specific dosing is individual and beyond general information, and human evidence for Amycretin is limited.
Administration at a glance (reference data)
- Route: Subcutaneous (sub-q form) or oral (oral form)
- Schedule: Once weekly (sub-q) or once daily (oral)
- Cycle length: Trial protocols
- Half-life: ~5-7 days (sub-q form)
References
- Amycretin (Novo Nordisk), early Phase 1/2 obesity readouts — Novo Nordisk pipeline, 2024-2025
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study — Dahl K et al., The Lancet, 2025
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist amycretin: a first-in-human, phase 1 trial — Gasiorek A et al., The Lancet, 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Amycretin
Last updated 2026-06-15.